Skip to content

Startup & venture capital news

Rouge Therapeutics raises USD 58m Series A

Specialist investors back an oral treatment for a hereditary bleeding disorder

By /

LinkedInX
Rouge Therapeutics: Rouge Therapeutics raises USD 58m Series A

Rouge Therapeutics announced USD 58 million in Series A funding on Tuesday 6 October 2026. BioGeneration Ventures, Angelini Ventures with the EIB Aurea facility, and Kurma Partners are named co-leads. The Netherlands company, also known as RougeTx, is a Leiden University Medical Center spinout developing an oral treatment for hereditary hemorrhagic telangiectasia. The financing supports its move toward clinical studies. Its investment story combines university-origin research with a defined rare-disease programme and specialist capital. Rouge's work remains a drug-development effort, with the round backing the research and preparation needed to advance the proposed treatment through the next stages of development.

Keep reading

More Funding

All stories